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Response to Yang et al.
We thank Yang et al. for their interest in our recent paper1
and for sharing their findings of a suspected Lynch syndrome
(LS) family meeting the Amsterdam I criteria and having a
biallelic frameshift variant (p.Asp206Thrfs*18) in MLH3. We
fully agree that more research is needed to establish a firm
basis for MLH3 variant interpretation and that strict criteria
need to be applied to any novel disease-causing variants. We
would like to address some points raised by Yang et al.2 as to
why MLH3 variants might be considered disease-causing.
MLH3 is one of three alternative partners known to complex
with MLH1 in postreplicative mismatch repair (MMR), the
other two being PMS1 and PMS2.3 The MLH1/PMS2 (MutLα)
complex is by far the most abundant. Cell line studies suggest
that MLH1/MLH3 (MutLγ) can partially compensate for the
lack of MutLα. Reduced penetrance is a common feature of
cancer-associated variants of PMS2. Pathogenic variants of
PMS2 give rise to LS with low penetrance when heterozygous
and display full penetrance with the clinical phenotype of
constitutional mismatch repair deficiency (CMMRD) syndrome
when homozygous.4 Many CMMRD patients with pathogenic
MMR gene variants develop gastrointestinal adenomas ranging
from a few polyps to profuse polyposis, resembling attenuated
adenomatous polyposis.5
Consistent with observations from CMMRD, adenomatous
polyposis was the leading phenotypic manifestation in
homozygous carriers of our MLH3 p.Ser1188Ter variant.
Combined with the lack of any microsatellite instability in
tumor tissue, a clear distinction relative to LS was made.1 All
biallelic carriers had polyposis (up to 100 polyps) and/or
cancer; the delayed onset (around 50 years) suggested reduced
penetrance. Some proven and obligatory heterozygous
carriers, too, were affected with mild polyposis or cancer.
Similarly, in the recessive polyposis syndromes associated
with pathogenic variants in MUTYH6 or NTHL1,7 a
proportion of heterozygous carriers are affected with cancers
considered to be part of the respective tumor spectra. Varying
penetrance and expressivity may complicate transmission
patterns especially if combined with inbreeding. In the family
described by Yang et al.,2 the mode of inheritance could, in
our opinion, be interpreted as autosomal dominant with
reduced penetrance, or autosomal recessive with dosage effect
and increased cancer risk in heterozygous carriers. In
agreement with our families, Yang et al.2 report the absence
of microsatellite instability in their family. We agree that the
family is unlikely to represent LS. We would be very
interested to know if the variant carriers exhibited any polyps,
which is currently not mentioned.
Our five families all shared a core haplotype of 0.8 Mb
around the MLH3 p.Ser1188Ter variant,1 suggesting a
common ancestral origin even though the pedigree informa-
tion available to us did not indicate any apparent connection
between the families. The shared region encompasses 15 other
genes, with none linked to any known cancer syndrome. We
detected no variants of possibly pathogenic significance in any
of these other genes by exome sequencing, leaving the MLH3
p.Ser1188Ter alteration the only variant of interest. Never-
theless, we agree with Yang et al.2 that genome sequencing
might be useful to rule out possible regulatory alterations in
noncoding regions.
According to Yang et al.,2 their MLH3 p.Asp206Thrfs*18
variant is predicted to be present in 4 of 7 MLH3 transcripts,
which would imply a chance of functional compensation by
wild-type isoforms. However, a recent investigation8 identifies
only two major isoforms, whereas the remaining five are
predicted in silico. Both the MLH3 p.Ser1188Ter variant and
the p.Asp206Thrfs*18 variant would equally affect the two
major isoforms; thus, no unaffected wild-type isoforms would
remain in either case.
Yang et al.2 note that contrary to the typical proximal
location of LS-associated colorectal tumors, the tumors in
their family resided in the rectum. Interestingly, in one of the
original papers proposing a connection between heterozygous
MLH3 variants and hereditary colon cancer predisposition,9 a
strong predominance of left-sided colon cancer was reported.
Furthermore, in CMMRD caused by pathogenic biallelic
PMS2 variants, left colon is the typical site of colon cancer.4
Even in the case of the established LS predisposition genes
MLH1, MSH2, MSH6, and PMS2, genotype–phenotype
relationships are poorly understood, including mechanisms
responsible for the essential clinical differences between
monoallelic and biallelic variant carriers. An exceptionally
high mutational load (“ultrahypermutation” phenotype)
following replication repair failure was recently detected in
CMMRD-associated brain tumors, which might explain why
brain tumors are common in CMMRD and develop at early
age; however, gastrointestinal polyps from CMMRD patients
showed no increased mutational load compared with adult
polyps, thus offering no insights to polyp predisposition in
CMMRD.10 In the case of MLH3, failing MMR may not be a
particularly promising candidate for a phenotypic determi-
nant in the first place, considering the observed redundancy
between MutLγ and MutLα and the resulting minor role for
MLH3 in MMR.3 As pointed out in Olkinuora et al.,1 MLH3 is
known to have many other cancer-relevant functions, whose
roles in tumors developing in MLH3 variant carriers remain
to be addressed by future studies.
In summary, we acknowledge the limitations of our
research, including the restriction of genetic screening to
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coding regions and lack of functional verification. However,
we do believe that the genetic and clinical evidence we
provide1 define a novel MLH3-associated polyposis
syndrome. Likewise, it seems likely that the family described
by Yang et al.2 represents a condition distinct from LS.
Additional multidisciplinary and multicenter research is
clearly warranted to better understand the role of MLH3
and its variants in cancer predisposition.
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